Roche stays mum about FTC, CMA re­views as $4.3B Spark deal faces yet an­oth­er de­lay. What's up?

Just what ex­act­ly is hold­ing up Roche’s $4.3 bil­lion ac­qui­si­tion of Spark Ther­a­peu­tics?

That’s the ques­tion that Spark in­vestors are pon­der­ing as the Swiss drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER